June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Real-world effectiveness of lifitegrast in dry eye disease patients across clinical practices in the US and Canada
Author Affiliations & Notes
  • Kelly K Nichols
    Optometry and Vision Science, The University of Alabama at Birmingham School of Optometry, Birmingham, Alabama, United States
  • John Hovanesian
    J. Harvard Eye Associates, California, United States
  • James A Katz
    The Midwest Center for Sight, Des Plaines, Illinois, United States
  • Annie Syntosi
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Arthur Chan
    Novartis Pharmaceuticals Corp, East Hanover, New Jersey, United States
  • Mrudula Glassberg
    Novartis Pharmaceuticals Corp, East Hanover, New Jersey, United States
  • Mitchell Jackson
    Jacksoneye, Lake Villa, Illinois, United States
  • Footnotes
    Commercial Relationships   Kelly Nichols, Alcon (F), Allergan (C), Bruder (C), Kala (C), Kala (F), NIH NEI (F), Oyster Point (C), Pentavision (C), Science Based Health (C), Shire/Novartis (C), Sight Sciences (C), TearFilm Innovations/Alcon/Acquiom (C), TearScience (F), Tear Solutions (F), TopiVert (C); John Hovanesian, Novartis (C), Novartis (F), Shire (C), Shire (F), Takeda (C), Takeda (F); James Katz, Alcon (C), Allergan (C), Eyevance Pharmaceuticals (C), Kala (C), Legrande (C), Novartis (C), Ocular Science (C), Ocular Therapeutix (C), Sun Pharmaceutical Industries (C); Annie Syntosi, Novartis Pharma AG (E); Arthur Chan, Novartis Pharmaceuticals Corporation (E); Mrudula Glassberg, Novartis Pharmaceuticals Corporation (E); Mitchell Jackson, Alcon (C), Allergan (C), Bausch and Lomb (C), Blephex (C), Bruder (C), Eyevance Pharmaceuticals (C), Johnson & Johnson (C), Kala (C), Novartis (C), Ocular Therapeutix (C), OysterPoint (C), Quidel (C), SightSciences (C), Sun Pharmaceutical Industries (C), TearLab (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1230. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kelly K Nichols, John Hovanesian, James A Katz, Annie Syntosi, Arthur Chan, Mrudula Glassberg, Mitchell Jackson; Real-world effectiveness of lifitegrast in dry eye disease patients across clinical practices in the US and Canada. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1230.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Dry eye disease (DED) is a chronic, multifactorial disease of the ocular surface. The purpose of this real-world clinical study was to assess the baseline characteristics and treatment outcomes in DED patients treated with lifitegrast for up to 12 months in the US and Canada.

Methods : A retrospective, non-comparative, optometrist and ophthalmologist panel-based chart review cohort study design including patients who initiated lifitegrast treatment between January 1, 2017 (US) or 1 January 2018 (Canada) and June 30, 2019 with an index date defined as the first day of lifitegrast treatment. Signs (corneal staining score; tear film break-up time) and symptoms of DED (eye dryness; blurred vision; ocular burning/stinging; foreign body sensation; ocular pain) were evaluated during the 6-month pre-index period and after 6 and 12 months of treatment with lifitegrast.

Results : A total of 600 lifitegrast-treated DED patients (76% female, mean age [standard deviation (SD)] 57 [13] years) were included in the study. Initial diagnosis of DED was determined by optometrists in 262 (44%) patients and ophthalmologists in 332 (55%) patients. Mean time from DED diagnosis to lifitegrast prescription was 23.3 months (SD 42.7) overall, and 31.5 (55.0), 23.8 (35.3) and 22.7 (48.4) for patients who initiated lifitegrast in 2017, 2018 and 2019, respectively. A total of 512 patients (92%) remained on treatment with lifitegrast at the 6-month follow-up period. Signs and symptoms of DED at the 6-month pre-index period (n=600 patients), Month 6 (n=534 patients) and Month 12 (n=320 patients) of follow-up, respectively were: (Fig. 1a-c, percentage of patients): eye dryness ([pre-index; Month 6; Month 12]: 87%; 7%; 3%); blurred vision (59%; 5%; 3%); ocular burning or stinging (55%; 3%; 1%); foreign body sensation (50%; 2%; 2%); ocular pain (12%; 1%;1%); corneal staining score (range 0–15) (median [95% Confidence Interval (CI)]: 6 [6–7]; 2 [1–5]; 2 [1–3]); tear film break-up time (median [95% CI]: 4 [3–12]; 8 [7–9]; 8 [7–8] seconds). Mean (SD) treatment duration for these patients was 28.5 (10.6), 15.9 (5.2) and 8.8 (2.6) months for patients with index dates in 2017, 2018 and 2019, respectively.

Conclusions : Lifitegrast significantly improved several signs and symptoms of DED in this real-world observational study, with the majority of patients remaining on treatment throughout the 12-month follow-up period.

This is a 2021 ARVO Annual Meeting abstract.



This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.